Sustained release (SR) tablets have emerged as a critical advancement in pharmaceutical technology, particularly for managing cardiovascular diseases (CVDs) requiring consistent drug plasma levels. This article explores the formulation, optimization, and characterization of SR tablets for cardiovascular drugs, focusing on their design to achieve prolonged therapeutic effects, improved patient compliance, and reduced side effects. Through experimental formulation of model drugs, such as metoprolol succinate, and comprehensive characterization techniques, including dissolution testing, hardness, and stability studies, this research evaluates the efficacy of SR systems. The results demonstrate that matrix-based SR tablets, utilizing hydrophilic polymers like hydroxypropyl methylcellulose (HPMC), provide controlled drug release over 24 hours. The study highlights formulation challenges, drug release kinetics, and stability under varying conditions, offering insights into scalable production and clinical applicability.Sustained release (SR) tablets for cardiovascular drugs represent a significant advancement in pharmaceutical technology, addressing the critical need for consistent drug plasma levels in managing cardiovascular diseases (CVDs). These formulations are designed to provide prolonged therapeutic effects, enhance patient compliance, and minimize side effects associated with frequent dosing. The article delves into the intricate process of formulating, optimizing, and characterizing SR tablets, using model drugs such as metoprolol succinate to demonstrate their efficacy. By employing matrix-based systems with hydrophilic polymers like hydroxypropyl methylcellulose (HPMC), these tablets achieve controlled drug release over a 24-hour period, ensuring a steady therapeutic effect.